Teva settles shareholder lawsuit over generic drug pricing for $420 mln


Reuters | Updated: 19-01-2022 02:33 IST | Created: 19-01-2022 02:33 IST
Teva settles shareholder lawsuit over generic drug pricing for $420 mln

Teva Pharmaceutical Industries Ltd has agreed to pay $420 million to settle shareholder litigation alleging the company hid an anti-competitive scheme to fix the price of generic drugs.

The settlement was disclosed on Tuesday in papers filed in federal court in Connecticut. The company did not admit to wrongdoing.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)

Give Feedback